Endogenous tissue-type plasminogen activator is protective during ascending urinary tract infection

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 801-808

  Roelofs, Joris J T H ^a,c   Rouschop, Kasper M A ^a,d   Teske, Gwendoline J D ^a   Wagenaar, Gerry T M ^b   Claessen, Nike ^a   Weening, Jan J ^a   Van Der Poll, Tom ^a   Florquin, Sandrine ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Fibrinolytic system; Neutrophil; Oxidative burst; Pyelonephritis; Tissue type plasminogen activator

Indexed keywords

FIBRIN; INTERLEUKIN 1BETA; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PYELONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE DELETION; KIDNEY PARENCHYMA; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; UPREGULATION; URINARY TRACT INFECTION;

ANIMALS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; FEMALE; MALE; MICE; MICE, INBRED C57BL; NEUTROPHILS; PHAGOCYTOSIS; PYELONEPHRITIS; RESPIRATORY BURST; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR;

EID: 60749096580     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn562     Document Type: Article

References (50)

1. Barnett BJ, Stephens DS. Urinary tract infection: an overview. Am J Med Sci 1997; 314: 245-249
2. Webb NJ, Brenchley PE. Cytokines and cell adhesion molecules in the inflammatory response during acute pyelonephritis. Nephron Exp Nephrol 2004; 96: e1-e6
3. Cotton SA, Gbadegesin RA, Williams S et al. Role of TGF-beta1 in renal parenchymal scarring following childhood urinary tract infection. Kidney Int 2002; 61: 61-67
4. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991; 4: 80-128
5. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720
6. Mulvey MA, Schilling JD, Martinez JJ et al. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci USA 2000; 97: 8829-8835
7. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 2004; 76: 760-781
8. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625
9. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82: 259-270
10. Sappino AP, Huarte J, Vassalli JD et al. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87: 962-970
11. Roelofs JJ, Rouschop KM, Leemans JC et al. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006; 17: 131-140
12. Hu K, Yang J, Tanaka S et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281: 2120-2127
13. Renckens R, Roelofs JJ, Florquin S et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 2006; 177: 1189-1196
14. Olszyna DP, Florquin S, Sewnath M et al. CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection. J Infect Dis 2001; 184: 301-307
15. Roelofs JJ, Rouschop KM, Teske GJ et al. The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int 2006; 70: 1942-1947
16. Hopkins WJ, Gendron-Fitzpatrick A, Balish E et al. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immun 1998; 66: 2798-2802
17. Rouschop KM, Sylva M, Teske GJD et al. Urothelial CD44 facilitates Escherichia coli infection of the murine urinary tract. J Immunol 2006; 177: 7225-7232
18. ter Horst SA, Wagenaar GT, de Boer E et al. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004; 97: 2014-2019
19. Renckens R, Roelofs JJ, ter Horst SA et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175: 6764-6771
20. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
22. Stuurman N, Pacios Bras C, Schlaman HR et al. Use of green fluorescent protein color variants expressed on stable broad-host-range vectors to visualize rhizobia interacting with plants. Mol Plant Microbe Interact 2000; 13: 1163-1169
23. Kampen AH, Tollersrud T, Lund A. Flow cytometric measurement of neutrophil respiratory burst in whole bovine blood using live Staphylococcus aureus. J Immunol Methods 2004; 289: 47-55
24. Florquin S, Van Den Berg JG, Olszyna DP et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001; 59: 2054-2061
25. Kitching AR, Holdsworth SR, Ploplis VA et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185: 963-968
26. Bickerstaff AA, Xia D, Pelletier RP et al. Mechanisms of graft acceptance: evidence that plasminogen activator controls donor-reactive delayed-type hypersensitivity responses in cardiac allograft acceptor mice. J Immunol 2000; 164: 5132-5139
27. Stringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic Biol Med 1997; 22: 985-988
28. Wang YF, Tsirka SE, Strickland S et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wildtype and tPA-deficient mice. Nat Med 1998; 4: 228-231
29. Cook AD, Braine EL, Campbell IK et al. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol 2002; 160: 917-926
30. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol 2001; 167: 1047-1052
31. Sato J, Schorey J, Ploplis VA et al. The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection. Am J Pathol 2003; 163: 517-531
32. Khalil A, Brauner A, Bakhiet M et al. Cytokine gene expression during experimental Escherichia coli pyelonephritis in mice. J Urol 1997; 158: 1576-1580
33. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283: R7-R28
34. Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 2004; 15: 844-853
35. Sanchez-Pernaute O, Largo R, Calvo E et al. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis 2003; 62: 1135-1138
36. Stringer KA, Lindenfeld J, Repine AJ et al. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 1997; 21: 27-34
37. Obel N, Andersen PL, Andersen HR. Preserved oxidative activity and chemotaxis of circulating neutrophils in patients with acute myocardial infarction. Eur Heart J 1993; 14: 790-794
38. Wolfson M, McPhail LC, Nasrallah VN et al. Phorbol myristate acetate mediates redistribution of protein kinase C in human neutrophils: potential role in the activation of the respiratory burst enzyme. J Immunol 1985; 135: 2057-2062
39. Gyetko MR, Aizenberg D, Mayo-Bond L. Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. J Leukoc Biol 2004; 76: 648-656
40. Plesner T, Ploug M, Ellis V et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994; 83: 808-815
41. Pedersen TL, Plesner T, Horn T et al. Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy. Ultrastruct Pathol 2000; 24: 175-182
42. Wilson EL, Francis GE. Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells. J Exp Med 1987; 165: 1609-1623
43. Takamiya M, Saigusa K, Kumagai R et al. Studies on mRNA expression of tissue-type plasminogen activator in bruises for wound age estimation. Int J Legal Med 2005; 119: 16-21
44. Moir E, Booth NA, Bennett B et al. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001; 113: 72-80
45. Strickland DK, Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J Thromb Haemost 2003; 1: 1663-1670
46. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992; 269: 375-382
47. Kang HM, Choi KS, Kassam G et al. Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med 1999; 9: 92-102
48. Rescher U, Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004; 117: 2631-2639
49. McVoy LA, Kew RR. CD44 and annexin A2 mediate the C5a chemotactic cofactor function of the vitamin D binding protein. J Immunol 2005; 175: 4754-4760
50. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-3358